---
ID: 4319
post_title: >
  Ex-drug executive Shkreli pleads not
  guilty to latest charge
author: Staff Writer
post_date: 2016-06-06 19:19:07
post_excerpt: ""
layout: post
permalink: >
  https://www.whenitson.com/ex-drug-executive-shkreli-pleads-not-guilty-to-latest-charge/
published: true
original_cats:
  - domesticNews
original_title:
  - >
    Ex-drug executive Shkreli pleads not
    guilty to latest charge
original_link:
  - >
    http://feeds.reuters.com/~r/Reuters/domesticNews/~3/SgYi2wCYVaQ/us-usa-crime-shkreli-idUSKCN0YS21F
canonical_url:
  - >
    http://feeds.reuters.com/~r/Reuters/domesticNews/~3/SgYi2wCYVaQ/us-usa-crime-shkreli-idUSKCN0YS21F
---
 [ad_1]
<br><div id="articleText">
<span id="midArticle_start"/>

<span id="midArticle_0"/><span class="focusParagraph" readability="6"><p><span class="articleLocation">NEW YORK</span> Former pharmaceutical executive Martin Shkreli, a lightning rod for outrage over soaring U.S. prescription drug prices, pleaded not guilty on Monday to an additional criminal charge that federal prosecutors filed against him last week.</p></span><span id="midArticle_1"/><p>Shkreli, 33, was indicted in December on seven criminal counts, including securities fraud. Prosecutors on Friday added an eighth charge, saying Shkreli tried to conceal from investors his control over shares in Retrophin Inc (<span id="symbol_RTRX.O_0">RTRX.O</span>).</p><span id="midArticle_2"/><p>Evan Greebel, former outside counsel to Retrophin, also pleaded not guilty to the charge at a court hearing in the New York City borough of Brooklyn. Greebel faces two counts in all.</p><span id="midArticle_3"/>
        
        <span class="first-article-divide"/><p>Shkreli last year sparked outrage among patients, medical societies and U.S. lawmakers after another company he ran, Turing Pharmaceuticals, raised the price of Daraprim by more than 5,000 percent to $750 a pill.</p><span id="midArticle_4"/>
        
        <span class="second-article-divide"/><p>In December, U.S. authorities arrested him on fraud charges unrelated to the pricing of Daraprim, saying he ran his investment funds and companies almost like a Ponzi scheme.</p><span id="midArticle_5"/><p>U.S. District Judge Kiyo Matsumoto declined during Monday's hearing to set a trial date for Shkreli and Greebel but said she was considering an early 2017 time frame.</p><span id="midArticle_6"/>
        
        <span class="third-article-divide"/><span id="midArticle_7"/><p> (Reporting by David Ingram; Editing by Chris Reese and Lisa Von Ahn)</p><span id="midArticle_8"/></div>
<br>[ad_2]
<br><a href="http://feeds.reuters.com/~r/Reuters/domesticNews/~3/SgYi2wCYVaQ/us-usa-crime-shkreli-idUSKCN0YS21F">Source </a>